Table 2. Patient characteristics of vaccination study.
| Patient | Peptide Dose (mg) | Age (years) | Sex | Etiology a | Stage of HCC | ALT (IU/L) | AFP (ng/ml) | Child-Pugh (A/B/C) | Histology of liver b | Treatment c | Immune Response (before/after) | Toxicity d (grade) | Recurrence (at 300 days after vaccination) | Relapse-free Survival (days) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A1 | 0.03 | 69 | M | HBV | II | 26 | 5 | A | ND (LC) | RFA | -/+ | None | + | 280 |
| A2 | 0.03 | 71 | M | Others | III | 24 | 4 | A | F3 | TACE, RFA | -/+ | P(1), S(1) | + | 113 |
| A3 | 0.03 | 67 | M | HCV | II | 34 | 4 | A | F3A1 | RFA | +/- | Pa(1) | - | 442 |
| B1 | 0.3 | 62 | M | HCV | I | 78 | 49 | A | F3A2 | RFA | -/+ | None | - | 329 |
| B2 | 0.3 | 66 | M | HCV | II | 37 | 11 | A | F4A2 | RFA | +/+ | None | + | 189 |
| B3 | 0.3 | 74 | M | HBV | II | 50 | 2 | A | F3A2 | RFA | -/+ | P(1), S(1) | - | 460 |
| C1 | 3 | 67 | F | HCV | II | 35 | 11 | A | F2A1 | RFA | +/+ | P(1), S(1) | - | 536 |
| C2 | 3 | 69 | F | Others | II | 22 | 24 | A | ND (LC) | RFA | -/- | P(1), S(1) | + | 133 |
| C3 | 3 | 69 | M | HCV | I | 27 | 8 | A | F4A1 | RFA | +/+ | Pa(1) | - | 810 |
| C4 | 3 | 72 | M | HCV | I | 31 | 8 | A | F3A2 | RFA | +/- | P(1), S(1) | + | 260 |
| C5 | 3 | 77 | F | HBV | II | 22 | 183 | A | F4A1 | RFA | +/+ | P(1), S(1) | - | 647 |
| C6 | 3 | 83 | M | HCV | I | 24 | 4 | A | F1A1 | RFA | +/- | None | - | 693 |
a HBV: hepatitis B virus; HCV: hepatitis C virus.
b Histology of the liver; ND: not determined, LC: liver cirrhosis.
c Treatment of HCC; RFA: radiofrequency ablation, TACE: transarterial chemoembolization
d Toxicity; P: Pruritus, Pa: Pain, S: Skin induration.